The primary challenges involve maintaining product quality and yield. Key issues include efficiently separating full (genome-containing) capsids from empty ones, removing process-related impurities like host cell DNA and proteins, and ensuring the final formulation is stable. Each step, from clarification to final filtration, must be optimized to prevent vector aggregation and loss of potency, which requires deep expertise in both the vector’s biology and chromatography methods.

For novel or engineered capsids, a standard platform purification process may not be optimal. We initiate a tailored process development program. This involves screening various chromatography resins and buffer conditions to identify a purification train that specifically matches the capsid’s surface charge and biophysical properties. This data-driven approach ensures high purity and recovery for next-generation vectors that fall outside the parameters of common serotypes like AAV8 or AAV9.

Analytical development is inseparable from purification because you can only purify what you can accurately measure. Phase-appropriate analytical assays are required at every step to quantify titer, assess the full-to-empty capsid ratio, measure purity, and confirm potency. Without robust, qualified analytics, it is impossible to validate that a downstream process is effectively removing impurities and preserving the quality of the final AAV product for IND-enabling toxicology studies.

The transition from small-scale AAV production to a scalable manufacturing process capable of supplying clinical programs hinges on a robust and reproducible downstream purification strategy. While upstream advancements have increased raw vector yields, the ultimate success of a therapeutic candidate depends on the ability to isolate a pure, potent, and safe final product. This is a core competency that underpins our work in [Large-Scale AAV Manufacturing and Process Development](/large-scale-aav-manufacturing-and-process-development/).

The requirement for scalable, clinical-grade AAV production methods has been a consistent theme in the field for over a decade (PMID: 19618999). A well-designed downstream process directly addresses this by creating a viable path to generating sufficient material for comprehensive GxP-compliant studies and eventual commercial supply.